氨磺必利与利培酮治疗首发精神分裂症疗效和安全性

Efficacy and Safety of Amisulpride and Risperidone in the Treatment of First-episode Schizophrenia

目的对氨磺必利与利培酮治疗首发精神分裂症的临床疗效和安全性进行分析。方法入选该次研究64例首发精神分裂症患者收治时间均为2017年3月—2018年3月,以计算机数字表法分为对照组与实验组,每组各32例,分别予以利培酮与氨磺必利进行治疗,经治疗后对比两组患者治疗效果。结果①两组患者治疗总有效率(68.7%VS90.6%)比较,数据差异有统计学意义(χ^2=4.730,P=0.030<0.05)。②两组患者不良反应发生率(25.0%、31.3%、43.7%VS6.3%、9.4%、15.6%)比较,数据差异有统计学意义(χ^2=4.267,P=0.039<0.05;χ^2=4.730、P=0.030<0.05;χ^2=6.063,P=0.014<0.05)。③实验组激活性(1.0±0.2)分、思维障碍(2.0±0.6)分、偏执(2.9±0.8)分、抑郁(1.1±0.3)分、攻击性评分为(2.0±0.6)分,实验组患者临床症状量表评分均低于对照组(t=18.407、P=0.000,t=17.287、P=0.000,t=12.061、P=0.000、t=16.254,P=0.000、t=12.605、P=0.000)。结论氨磺必利治疗首发精神分裂症的效果较为理想,且具有较高的安全性,其效果得到患者与临床的认可。

Objective To analyze the clinical efficacy and safety of amisulpride and risperidone in the treatment of first-episode schizophrenia.Methods Sixty-four patients with first-episode schizophrenia were enrolled in the study from March 2017 to March 2018.They were divided into a control group and an experimental group by computerized digital table.Each group received 32 cases,respectively.Ketone and amisulpride were treated,and the therapeutic effects of the two groups were compared after treatment.Results 1.The total effective rate of treatment(68.7%vs.90.6%)was statistically significant(χ^2=4.730,P=0.030<0.05).2.The incidence of adverse reactions in the two groups(25.0%,31.3%,43.7%vs 6.3%,9.4%,15.6%)were statistically significant(χ^2=4.267,P=0.039<0.05;χ^2=4.730,P=0.030<0.05;χ^2=6.063,P=0.014<0.05).3.experimental group activation(1.0±0.2)points,thinking disorder(2.0±0.6)points,paranoid(2.9±0.8)points,depression(1.1±0.3)points,aggression score(2.0±0.6)points,experimental group of patient's clinical symptom scale scores were lower than the control group(t=18.407,P=0.000;t=17.287,P=0.000;t=12.061,P=0.000,t=16.254,P=0.000,t=12.605,P=0.000).Conclusion Amisulpride is effective in the treatment of first-episode schizophrenia,and it has high safety.Its effect is recognized by patients and clinics.